Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma
- PMID: 16227802
- DOI: 10.1097/01.aids.0000189855.06194.ce
Evidence of activity of Irinotecan in patients with advanced AIDS-related Kaposi's sarcoma
Abstract
Fourteen HIV-infected patients with advanced Kaposi's sarcoma (KS) received Irinotecan 150 mg/m intravenously on days 1 and 10. All patients were relapsed/progressed during highly active antiretroviral therapy, administered as primary antineoplastic therapy. An objective response, all partial remissions, occurred in 75% of patients. Irinotecan was well tolerated, severe leukopenia occurred in only 33% of patients. In HIV-infected patients with advanced KS, irinotecan is active and well tolerated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical